NewsValidation Anticipated For Thousands Of UK CBD Products -...

Validation Anticipated For Thousands Of UK CBD Products – As Almost 100 Products Taken Off Public List


THOUSANDS of CBD businesses are expecting to have their products validated over the coming weeks with two of the main Novel Food consortia submitting their completed applications to UK and European authorities.

In a press release the Association for the Cannabinoid Industry – which is representing around one-third of total applicants – says it submitted its application, along with toxicology studies, to the UK Food Standards Agency.

Likewise, the European Industrial Hemp Association (EIHA) which represents some 170 Companies, also with thousands of products, submitted applications to be validated for its CBD isolate and synthetic CBD to the FSA and the European Food Safety Authority (EFSA) on Friday November 4.

Lower Daily Intake

EIHA’s submission also included details of its toxicology studies and as a result of the findings it is recommending an acceptable daily intake (ADI) for CBD of 17.5mg per day.

This is well below the current levels recommended by the UK FSA of 70mg per day.

Lorenza Romanese, Managing Director, of EIHA told BusinessCann: “For the isolate CBD we observed effects in four organs, including the liver and the kidney

“Therefore, the derived NOAEL (non-observable adverse effect level) is lower than we initially expected and lower than what is indicated in the existing literature. 

“This led us to infer an Acceptable Daily Intake (ADI) of 17.5 mg (one milligram or thousandth of a gram) per day of CBD, which has been proposed to EFSA and FSA.”

Higher Level For Full Spectrum

However, she went on to say that it expects the findings from the toxicology studies with its full-spectrum CBD – to be submitted early next year – will recommend a higher ADI due to its ‘less concentrated formulation’ and ‘promising preliminary results’.

In a letter to members EIHA goes on to say that formulations must contain a maximum CBD content of 10% and additional labelling requirements will be needed including not recommending use for children, pregnant and lactating women, or for it to be consumed alongside any other hemp food product. 

Earlier this year the UK FSA published the complete version of its Public List which features over 200 suppliers covering over 12,000 products.

Public List Removals

However, since then almost 100 products have been removed from the list for a variety of reasons.

An FSA spokesperson told BusinessCann: “We don’t release information on why individual products are removed from the list, but removal can be due to various reasons, for example: at request of the applicant, to remove duplicates, or because they do not comply with other aspects of food law.”

One company which has seen one of its products removed is UK firm Savage Cabbage. Its product is a ‘CBDa Full Spectrum Hemp Extract 30ml Natural Flavour’.

Jade Proudman, CEO of Savage Cabbage, told BusinessCann:  “The FSA have made an interesting decision as they have stated that any product that reference CBDa as its primary description must have its own Novel Food Application. 

“As our Savage Cabbage CBDa oil is an isolated compound which is mixed with CBD and is not one of our full spectrum products it will be removed from the shelves under this rule. Whilst we understand their current position we find it frustrating and do not feel this is a science based decision.”

In relation to the ACI application it also said that it is currently collating the data required to support its members EFSA novel food submissions. 

The ACI refused to comment further on its applications saying it will ‘wait until its receives feedback from the FSA on the status of its data package’. 

Just a handful of products on the Public List have been validated to date. Once validated they will have to undergo a risk assessment before being finally authorised for sale.

A full list of the items which have now been removed from the public list is featured below.

Peter McCusker is an experienced news and business editor, who believes it’s time to fully embrace the multiple, proven, medical benefits of the cannabis plant.

Latest news

Treasury Should “Unlock” Cannabis Economic Benefits, Says CIC

PRESS RELEASE THE Treasury has been urged to ”unlock the very significant economic potential” of the medical cannabis, hemp, and...

Bloomwell Group Closes Multi-Million Euro Growth Capital Round With Leading US Venture Capital Investors, And Award-Winning Actor, Moritz Bleibtreu

PRESS RELEASE FRANKFURT-based medical cannabis holding company Bloomwell Group (“Bloomwell,” “Bloomwell Group,” or the “Company”) has closed a significant multi-million Euro funding...

Norway Hosts First Public Meeting On Medical Cannabis Amid ‘Early First Steps’ Towards Potential Reform

NORWAY, one of the most cautious states in Europe when it comes to cannabis liberalisation, recently held a public...

Cutbill Jacoby PR Launches To Focus On Emerging Industries

PRESS RELEASE Cutbill Jacoby, a London-based Communications and PR agency for emerging industries, launches to initially service the fast-growing industrial...

Sana Healthcare Becomes Script Assist: Company Rebrands To Focus On Innovative Problem-Solving Platform

SANA Healthcare will from today be known as Script Assist after the company’s innovative platform which provides clinicians with...

Love Hemp ‘Rigorously Refutes’ Allegations Of Fraud Levelled By Former Managing Director

LOVE Hemp has responded to damning allegations made publicly by its former managing director Philip Small, who left the...

Must read

Love Hemp ‘Rigorously Refutes’ Allegations Of Fraud Levelled By Former Managing Director

LOVE Hemp has responded to damning allegations made publicly...

You might also likeRELATED
Recommended to you